Hexabrix and Plavix drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Hexabrix and Plavix. Common interactions include pruritus among females and anaphylactic shock among males.

The phase IV clinical study analyzes what interactions people who take Hexabrix and Plavix have. It is created by eHealthMe based on reports of 30 people who take Hexabrix and Plavix from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Nov, 27, 2022

30 people who take Hexabrix and Plavix together, and have interactions are studied.


What is Hexabrix?

Hexabrix has active ingredients of ioxaglate meglumine; ioxaglate sodium. eHealthMe is studying from 448 Hexabrix users for its effectiveness, alternative drugs and more.

What is Plavix?

Plavix has active ingredients of clopidogrel bisulfate. It is often used in blood clots. eHealthMe is studying from 145,095 Plavix users for its effectiveness, alternative drugs and more.

Number of Hexabrix and Plavix reports submitted per year:

Hexabrix and Plavix drug interactions.

Common Hexabrix and Plavix drug interactions by gender *:

female:

  1. Pruritus
  2. Pulmonary oedema
  3. Rash generalised
  4. Reflex sympathetic dystrophy
  5. Renal failure acute on chronic
  6. Sepsis
  7. Synovitis
  8. Tenderness
  9. Tenosynovitis
  10. Thrombosis

male:

  1. Anaphylactic shock
  2. Blood pressure decreased
  3. Anisocytosis
  4. Arrhythmia
  5. Atrial fibrillation
  6. Blood creatinine increased
  7. Blood urea increased
  8. Bradycardia
  9. C-reactive protein increased
  10. Cardiac arrest

Common Hexabrix and Plavix drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Anaphylactic shock

40-49:

  1. Injection site haemorrhage
  2. Jaundice
  3. Metabolic acidosis
  4. Multi-organ failure
  5. Neutropenia
  6. Oliguria
  7. Polychromasia
  8. Pyrexia
  9. Restlessness
  10. Sepsis

50-59:

  1. Pain
  2. Pruritus
  3. Pyrexia
  4. Anhedonia
  5. Anxiety
  6. Cerebrovascular accident
  7. Death
  8. Depression
  9. Fear
  10. Injury

60+:

  1. Blood pressure decreased
  2. Anaphylactic shock
  3. Contrast media allergy
  4. Dyspnoea
  5. Erythema
  6. Malaise
  7. Purpura
  8. Aggression
  9. Anaphylactic reaction
  10. Angina pectoris

Common conditions people have *:

  1. Acute Coronary Syndrome (acute chest pain and other symptoms that happen because the heart does not get blood): 2 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Hexabrix and Plavix?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Hexabrix and Plavix:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Plavix side effects:

Browse all side effects of Plavix:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Plavix interactions:

Browse all interactions between Plavix and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ioxaglate meglumine; ioxaglate sodium and clopidogrel bisulfate (the active ingredients of Hexabrix and Plavix, respectively), and Hexabrix and Plavix (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Hexabrix and Plavix.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: